Increase in cellular cyclic AMP concentrations reverses the profibrogenic phenotype of cardiac myofibroblasts: A novel therapeutic approach for cardiac fibrosis

Molecular Pharmacology

Volumn 84, Issue 6, 2013, Pages 787-793

  Lu, David ^a   Aroonsakool, Nakon ^a   Yokoyama, Utako ^a,e   Patel, Hemal H ^c,d   Insel, Paul A ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^d University of California   (United States)

^e YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; ADRENOMEDULLIN; ALPHA SMOOTH MUSCLE ACTIN; BERAPROST; BUTAPROST; COLLAGEN DERIVATIVE; COLLAGEN TYPE 1 ALPHA 1; CYCLIC AMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; FORSKOLIN; ISOPRENALINE; PLASMINOGEN ACTIVATOR INHIBITOR 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL ACTIVITY; CELL PROTECTION; CELL TRANSFORMATION; CONTROLLED STUDY; FIBROGENESIS; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART MUSCLE FIBROSIS; HEART PROTECTION; MALE; MYOFIBROBLAST; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

3',5'-CYCLIC-AMP PHOSPHODIESTERASES; ACTINS; ADENYLATE CYCLASE; ANIMALS; CELLS, CULTURED; COLFORSIN; COLLAGEN; CYCLIC AMP; FIBROBLASTS; FIBROSIS; ISOENZYMES; MALE; MYOCARDIUM; MYOFIBROBLASTS; PLASMINOGEN ACTIVATOR INHIBITOR 1; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84888857378     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.113.087742     Document Type: Article

References (33)

1. Bender AT and Beavo JA (2006) Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 58:488-520.
2. Bujak M and Frangogiannis NG (2007) The role of TGF-beta signaling in myocardial infarction and cardiac remodeling. Cardiovasc Res 74:184-195.
3. Creemers EE and Pinto YM (2011) Molecular mechanisms that control interstitial fibrosis in the pressure-overloaded heart. Cardiovasc Res 89:265-272.
4. Davaille J, Gallois C, Habib A, Li L, Mallat A, Tao J, Levade T, and Lotersztajn S (2000) Antiproliferative properties of sphingosine 1-phosphate in human hepatic myofibroblasts. A cyclooxygenase-2 mediated pathway. J Biol Chem 275:34628-34633.
5. Dunkern TR, Feurstein D, Rossi GA, Sabatini F, and Hatzelmann A (2007) Inhibition of TGF-beta induced lung fibroblast to myofibroblast conversion by phosphodiesterase inhibiting drugs and activators of soluble guanylyl cyclase. Eur J Pharmacol 572:12-22.
6. Fan D, Takawale A, Lee J, and Kassiri Z (2012) Cardiac fibroblasts, fibrosis and extracellular matrix remodeling in heart disease. Fibrogenesis Tissue Repair 5: 15-42.
7. Garrison G, Huang SK, Okunishi K, Scott JP, Kumar Penke LR, Scruggs AM, and Peters-Golden M (2013) Reversal of myofibroblast differentiation by prostaglandin E(2). Am J Respir Cell Mol Biol 48:550-558.
8. Ghosh AK and Vaughan DE (2012) PAI-1 in tissue fibrosis. J Cell Physiol 227: 493-507.
9. Goldsmith EC, Bradshaw AD, and Spinale FG (2013) Cellular mechanisms of tissue fibrosis. 2. Contributory pathways leading to myocardial fibrosis: moving beyond collagen expression. Am J Physiol Cell Physiol 304:C393-C402.
10. Heusinger-Ribeiro J, Eberlein M, Wahab NA, and Goppelt-Struebe M (2001) Expression of connective tissue growth factor in human renal fibroblasts: regulatory roles of RhoA and cAMP. J Am Soc Nephrol 12:1853-1861.
11. Hinz B (2007) Formation and function of the myofibroblast during tissue repair. J Invest Dermatol 127:526-537.
12. Hinz B, Celetta G, Tomasek JJ, Gabbiani G, and Chaponnier C (2001) Alpha-smooth muscle actin expression upregulates fibroblast contractile activity. Mol Biol Cell 12 :2730-2741.
13. Huang SK, Wettlaufer SH, Chung J, and Peters-Golden M (2008) Prostaglandin E2 inhibits specific lung fibroblast functions via selective actions of PKA and Epac-1. Am J Respir Cell Mol Biol 39:482-489.
14. Huang SK, White ES, Wettlaufer SH, Grifka H, Hogaboam CM, Thannickal VJ, Horowitz JC, and Peters-Golden M (2009) Prostaglandin E(2) induces fibroblast apoptosis by modulating multiple survival pathways. FASEB J 23: 4317-4326.
15. Insel PA, Murray F, Yokoyama U, Romano S, Yun H, Brown L, Snead A, Lu D, and Aroonsakool N (2012) cAMP and Epac in the regulation of tissue fibrosis. Br J Pharmacol 166:447-456.
16. Kisseleva T, Cong M, Paik Y, Scholten D, Jiang C, Benner C, Iwaisako K, Moore-Morris T, Scott B, and Tsukamoto H et al. (2012) Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis. Proc Natl Acad Sci USA 109: 9448-9453.
17. Kolodsick JE, Peters-Golden M, Larios J, Toews GB, Thannickal VJ, and Moore BB (2003) Prostaglandin E2 inhibits fibroblast to myofibroblast transition via E. prostanoid receptor 2 signaling and cyclic adenosine monophosphate elevation. Am J Respir Cell Mol Biol 29:537-544.
18. Kriz W, Kaissling B, and Le Hir M (2011) Epithelial-mesenchymal transition (EMT) in kidney fibrosis: fact or fantasy? J Clin Invest 121:468-474.
19. Leask A and Abraham DJ (2004) TGF-beta signaling and the fibrotic response. FASEB J 18:816-827.
20. Liu X, Ostrom RS, and Insel PA (2004) cAMP-elevating agents and adenylyl cyclase overexpression promote an antifibrotic phenotype in pulmonary fibroblasts. Am J Physiol Cell Physiol 286:C1089-C1099.
21. Miller CL, Cai Y, Oikawa M, Thomas T, Dostmann WR, Zaccolo M, Fujiwara K, and Yan C (2011) Cyclic nucleotide phosphodiesterase 1A: a key regulator of cardiac fibroblast activation and extracellular matrix remodeling in the heart. Basic Res Cardiol 106:1023-1039.
22. Parekh A, Sandulache VC, Lieb AS, Dohar JE, and Hebda PA (2007) Differential regulation of free-floating collagen gel contraction by human fetal and adult dermal fibroblasts in response to prostaglandin E2 mediated by an EP2/cAMP-dependent mechanism. Wound Repair Regen 15:390-398.
23. Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29:e45.
24. Schiller M, Dennler S, Anderegg U, Kokot A, Simon JC, Luger TA, Mauviel A, and Böhm M (2010) Increased cAMP levels modulate transforming growth factor-beta/Smad-induced expression of extracellular matrix components and other key fibroblast effector functions. J Biol Chem 285:409-421.
25. Snead AN and Insel PA (2012) Defining the cellular repertoire of GPCRs identifies a profibrotic role for the most highly expressed receptor, protease-activated receptor 1, in cardiac fibroblasts. FASEB J 26:4540-4547.
26. Swaney JS, Patel HH, Yokoyama U, Lai NC, Spellman M, Insel PA, and Roth DM (2007) Adenylyl cyclase activity and function are decreased in rat cardiac fibroblasts after myocardial infarction. Am J Physiol Heart Circ Physiol 293:H3216-H3220.
27. Swaney JS, Roth DM, Olson ER, Naugle JE, Meszaros JG, and Insel PA (2005) Inhibition of cardiac myofibroblast formation and collagen synthesis by activation and overexpression of adenylyl cyclase. Proc Natl Acad Sci USA 102:437-442.
28. Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, and Brown RA (2002) Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol 3:349-363.
29. van den Borne SW, Diez J, Blankesteijn WM, Verjans J, Hofstra L, and Narula J (2010) Myocardial remodeling after infarction: the role of myofibroblasts. Nat Rev Cardiol 7:30-37.
30. van der Vliet A and Bove PF (2011) Purinergic signaling in wound healing and airway remodeling. Subcell Biochem 55:139-157.
31. Windmeier C and Gressner AM (1997) Pharmacological aspects of pentoxifylline with emphasis on its inhibitory actions on hepatic fibrogenesis. Gen Pharmacol 29: 181-196.
32. Wynn TA (2008) Cellular and molecular mechanisms of fibrosis. J Pathol 214: 199-210.
33. Yokoyama U, Patel HH, Lai NC, Aroonsakool N, Roth DM, and Insel PA (2008) The cyclic AMP effector Epac integrates pro- and anti-fibrotic signals. Proc Natl Acad Sci USA 105:6386-6391.